From the lab bench to the cloud, Penn Medicine is at the forefront of biomedical discovery—translating research into real-world impact. Explore the latest breakthroughs.
Penn Medicine research is bringing the “sleeper” phase of cancer to light—creating hope that more cancers could be wiped out for good and never come back.
A reimagined facility has been introduced as the epicenter for pioneering Penn research aimed at “breaking the immunological code” of autoimmune diseases and bringing them to heel.
Penn Medicine researchers will present the latest advances in blood cancer and classical hematology research at the 2025 ASH Annual Meeting.
CAR T cell therapy could be a highly effective tool against atherosclerosis, a common condition that leads to heart attacks and stroke.
Three decades of training leaders and driving research that defines ethics in health care, policy, and innovation were honored with a national award.
New clues in pancreas lymph nodes and spleen could stop the disease before insulin is lost forever.
Brain recordings of a patient with obesity shows that tirzepatide (Mounjaro) only temporarily suppresses signaling related to food noise.
Public investments in biomedical research have an outsized effect, driving new scientific insights, economic growth, and ultimately treatments and cures.
The successes of CAR T research show the importance of the cycle of science—sparking new ideas and clinical trials that give patients better options.
The Penn Medicine Co-Investment program spurs faculty innovation, creates jobs, and helps scale up ideas into large-scale clinical studies.
A first-of-its-kind clinical trial identified risk of breast cancer recurrence and successfully treated dormant tumor cells using existing drugs.
In a historic medical breakthrough, a child with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy.
Penn Medicine and Wharton researchers partner to create CellSpectra and SISKA, offering clues to better treatments for kidney disease and beyond.
Blocking a rise in oxygen levels at the site of a bone break led to greater blood vessel formation and improved bone regeneration, according to Penn Medicine researchers. — Nov. 11, 2025
Engineering immune receptors related to the IL-9 gene into CAR T cells made them effective and persistent against pancreatic and prostate tumors, even in low doses. — Nov. 21, 2025
"Reproducible Brain Charts” harmonized data from high-quality MRI studies of young people to potentially map how psychiatric illness is tied to brain development. — Nov. 19, 2025
Clinical research professionals’ quiet work with patients and data behind the scenes is vital to moving innovative research forward.
A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.
Carl June, MD, explains how CAR T cell therapy, which has been transformative for blood cancers, holds the potential to help millions more patients.
Bilateral hand transplant at Penn Medicine gives Swiss man new hands 16 years after childhood amputations.
Uterus transplant is still a rare procedure—but for the six moms who have had eight babies to date through Penn’s program, it means the world.
In a proof of concept for a future bridge to transplant, researchers circulated a deceased donor’s blood through a genetically engineered pig liver.
Every minute in the U.S., a woman needs a blood transfusion due to her period. Kathleen O’Neill, MD, is working to develop a novel therapy to protect women.
Could the mRNA technology behind COVID vaccines be used to tamp down the immune system for celiac and other autoimmune diseases?
Biomedical innovations using mRNA could prevent, treat, or cure numerous diseases. Penn Medicine is advancing its Nobel Prize-winning technology worldwide.
The Basser Center for BRCA is running an innovative cancer interception clinical trial that depends on volunteers with deep, personal ties to cancer.
Penn Medicine researchers are at the forefront of new scientific efforts to interrupt the development of cancer at its earliest stages.
The gift from Penn alumni Mindy and Jon Gray establishes the Basser Cancer Interception Institute to stop hereditary cancers at the earliest stages.
Subscribe to Penn Medicine newsletters and publications for the latest developments.
